{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:44Z","timestamp":1789084844369,"version":"build-2803163510"},"reference-count":91,"publisher":"Tech Science Press","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["OR"],"published-print":{"date-parts":[[2025]]},"DOI":"10.32604\/or.2025.066228","type":"journal-article","created":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T08:48:31Z","timestamp":1756111711000},"page":"2657-2672","source":"Crossref","is-referenced-by-count":6,"title":["Predictive Value of Serum VEGF Levels in Non-Small Cell Lung Cancer: A Review"],"prefix":"10.32604","volume":"33","author":[{"given":"Eleni","family":"Kokkotou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andriani","family":"Charpidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Syrigos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"17807","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","article-title":"Lung cancer","volume":"398","author":"Thai","year":"2021","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1158\/1078-0432.CCR-16-1968","article-title":"Exploring the benefit\/risk associated with antiangiogenic agents for the treatment of non-small cell lung cancer patients","volume":"23","author":"Kurzrock","year":"2017","journal-title":"Clin Cancer Res"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nrd1381","article-title":"Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer","volume":"3","author":"Ferrara","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1634\/theoncologist.2014-0465","article-title":"Targeting angiogenesis in cancer therapy: moving beyond vascular endothelial growth factor","volume":"20","author":"Zhao","year":"2015","journal-title":"Oncologist"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S0140-6736(15)01088-0","article-title":"Antiangiogenic therapy in oncology: current status and future directions","volume":"388","author":"Jayson","year":"2016","journal-title":"Lancet"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41540-017-0037-9","article-title":"VEGFR1 promotes cell migration and proliferation through PLC\u03b3 and PI3K pathways","volume":"4","author":"Weddell","year":"2018","journal-title":"npj Syst Biol Appl"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.3390\/ijms21041388","article-title":"Role of VEGFs\/VEGFR-1 signaling and its inhibition in modulating tumor invasion: experimental evidence in different metastatic cancer models","volume":"21","author":"Ceci","year":"2020","journal-title":"Int J Mol Sci"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1042\/bst0311171","article-title":"VEGF signalling: integration and multi-tasking in endothelial cell biology","volume":"31","author":"Zachary","year":"2003","journal-title":"Biochem Soc Trans"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1006\/mvre.2001.2338","article-title":"VEGF increases permeability of the endothelial cell monolayer by activation of PKB\/akt, endothelial nitric-oxide synthase, and MAP kinase pathways","volume":"62","author":"Lal","year":"2001","journal-title":"Microvasc Res"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.yexcr.2013.02.021","article-title":"Regulation of angiogenesis by PI3K signaling networks","volume":"319","author":"Graupera","year":"2013","journal-title":"Exp Cell Res"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1006\/excr.2000.5102","article-title":"VEGF-induced activation of phosphoinositide 3-kinase is dependent on focal adhesion kinase","volume":"263","author":"Qi","year":"2001","journal-title":"Exp Cell Res"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1200\/JCO.2001.19.2.577","article-title":"Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival","volume":"19","author":"Ugurel","year":"2001","journal-title":"J Clin Oncol"},{"key":"ref14","first-page":"172","article-title":"Expression of vascular permeability factor\/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis","volume":"56","author":"Claffey","year":"1996","journal-title":"Cancer Res"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1038\/nm.1877","article-title":"Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangioma","volume":"14","author":"Jinnin","year":"2008","journal-title":"Nat Med"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41392-025-02249-0","article-title":"Vascular endothelial growth factor signaling in health and disease: from molecular mechanisms to therapeutic perspectives","volume":"10","author":"Lee","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/mc.23291","article-title":"Alternative splicing: an important regulatory mechanism in colorectal carcinoma","volume":"60","author":"Wang","year":"2021","journal-title":"Mol Carcinog"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.3390\/genes12071085","article-title":"Alternative RNA splicing\u2014the Trojan horse of cancer cells in chemotherapy","volume":"12","author":"Mehterov","year":"2021","journal-title":"Genes"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"15585","DOI":"10.3390\/ijms232415585","article-title":"The VEGF\/VEGFR axis revisited: implications for cancer therapy","volume":"23","author":"Mabeta","year":"2022","journal-title":"Int J Mol Sci"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3892\/ol.2022.13489","article-title":"Immunosuppressive effects of vascular endothelial growth factor","volume":"24","author":"Ribatti","year":"2022","journal-title":"Oncol Lett"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1359069","DOI":"10.3389\/fonc.2024.1359069","article-title":"Mechanisms of angiogenesis in tumour","volume":"14","author":"Zhang","year":"2024","journal-title":"Front Oncol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/JLB.3A0120-050RR","article-title":"Melanoma-derived extracellular vesicles skew neutrophils into a pro-tumor phenotype","volume":"111","author":"Guimar\u00e3es-Bastos","year":"2022","journal-title":"J Leukoc Biol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.3389\/fimmu.2019.01445","article-title":"Human skin-derived mast cells spontaneously secrete several angiogenesis-related factors","volume":"10","author":"McHale","year":"2019","journal-title":"Front Immunol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.3390\/ijms20092106","article-title":"Mast cells, angiogenesis and lymphangiogenesis in human gastric cancer","volume":"20","author":"Sammarco","year":"2019","journal-title":"Int J Mol Sci"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"6140","DOI":"10.3390\/ijms20246140","article-title":"Hypoxia: overview on hypoxia-mediated mechanisms with a focus on the role of HIF genes","volume":"20","author":"Tirpe","year":"2019","journal-title":"Int J Mol Sci"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"3845","DOI":"10.7150\/ijbs.70958","article-title":"VEGF\/VEGFR-targeted therapy and immunotherapy in non-small cell lung cancer: targeting the tumor microenvironment","volume":"18","author":"Zhao","year":"2022","journal-title":"Int J Biol Sci"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1080\/14728222.2017.1371137","article-title":"VEGF as a potential target in lung cancer","volume":"21","author":"Frezzetti","year":"2017","journal-title":"Expert Opin Ther Targets"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/nrc3627","article-title":"VEGF targets the tumour cell","volume":"13","author":"Goel","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.canlet.2019.11.009","article-title":"Immune cells within the tumor microenvironment: biological functions and roles in cancer immunotherapy","volume":"470","author":"Lei","year":"2020","journal-title":"Cancer Lett"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.3390\/cells10092361","article-title":"The immune privilege of cancer stem cells: a key to understanding tumor immune escape and therapy failure","volume":"10","author":"Galassi","year":"2021","journal-title":"Cells"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1084\/jem.20140559","volume":"212","author":"Voron","year":"2015","journal-title":"J Exp Med"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1158\/2326-6066.CIR-19-0360","volume":"8","author":"de Almeida","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1007\/s00432-022-04326-1","volume":"149","author":"Zhang","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41420-022-01101-6","article-title":"Emerging mechanisms of pyroptosis and its therapeutic strategy in cancer","volume":"8","author":"Lu","year":"2022","journal-title":"Cell Death Discov"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"635862","DOI":"10.3389\/fimmu.2021.635862","article-title":"Fas\/FasL signaling regulates CD8 expression during exposure to self-antigens","volume":"12","author":"Flores-Mendoza","year":"2021","journal-title":"Front Immunol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"4878","DOI":"10.1182\/blood-2002-07-1956","article-title":"VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression","volume":"101","author":"Ohm","year":"2003","journal-title":"Blood"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/cr.2016.151","article-title":"Regulatory T cells in cancer immunotherapy","volume":"27","author":"Tanaka","year":"2017","journal-title":"Cell Res"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"39658","DOI":"10.18632\/oncotarget.17340","article-title":"Clinicopathologic and prognostic significance of regulatory T cells in patients with hepatocellular carcinoma: a meta-analysis","volume":"8","author":"Sun","year":"2017","journal-title":"Oncotarget"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"616837","DOI":"10.3389\/fimmu.2021.616837","article-title":"Direct and indirect modulation of T cells by VEGF-A counteracted by anti-angiogenic treatment","volume":"12","author":"Bourhis","year":"2021","journal-title":"Front Immunol"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges","volume":"15","author":"Fukumura","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"234","DOI":"10.3892\/ol.2020.12097","article-title":"Targeting tumor-associated macrophages in the tumor microenvironment (review)","volume":"20","author":"Zhou","year":"2020","journal-title":"Oncol Lett"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.cmet.2019.06.001","article-title":"Macrophages and metabolism in the tumor microenvironment","volume":"30","author":"Vitale","year":"2019","journal-title":"Cell Metab"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s12943-019-1022-2","article-title":"Targeting Tyro3, Axl and MerTK (TAM receptors): implications for macrophages in the tumor microenvironment","volume":"18","author":"Myers","year":"2019","journal-title":"Mol Cancer"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s13045-019-0760-3","article-title":"Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications","volume":"12","author":"Lin","year":"2019","journal-title":"J Hematol Oncol"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1186\/s12967-020-02618-z","article-title":"Tumor-associated macrophage, angiogenesis and lymphangiogenesis markers predict prognosis of non-small cell lung cancer patients","volume":"18","author":"Hwang","year":"2020","journal-title":"J Transl Med"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"1758835919891622","DOI":"10.1177\/1758835919891622","article-title":"NF-\u03baB activation triggers NK-cell stimulation by monocyte-derived dendritic cells","volume":"11","author":"Bosch","year":"2019","journal-title":"Ther Adv Med Oncol"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3390\/cancers13030433","article-title":"Dendritic cells: behind the scenes of T-cell infiltration into the tumor microenvironment","volume":"13","author":"Lucarini","year":"2021","journal-title":"Cancers"},{"key":"ref48","first-page":"3777","article-title":"Role of hypoxia in inhibiting dendritic cells by VEGF signaling in tumor microenvironments: mechanism and application","volume":"11","author":"Han","year":"2021","journal-title":"Am J Cancer Res"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/nrclinonc.2018.9","volume":"15","author":"Khan","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1111\/cas.14091","article-title":"Vascular endothelial growth factor (VEGF) impairs the motility and immune function of human mature dendritic cells through the VEGF receptor 2-RhoA-cofilin1 pathway","volume":"110","author":"Long","year":"2019","journal-title":"Cancer Sci"},{"key":"ref51","first-page":"3480","article-title":"The influence of dendritic cell infiltration and vascular endothelial growth factor expression on the prognosis of non-small cell lung cancer","volume":"8","author":"Inoshima","year":"2002","journal-title":"Clin Cancer Res"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.immuni.2021.04.004","article-title":"MDSC: markers, development, states, and unaddressed complexity","volume":"54","author":"Hegde","year":"2021","journal-title":"Immunity"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"104254","DOI":"10.1016\/j.cellimm.2020.104254","article-title":"IL-6 as a major regulator of MDSC activity and possible target for cancer immunotherapy","volume":"359","author":"Weber","year":"2021","journal-title":"Cell Immunol"},{"key":"ref54","first-page":"1755","article-title":"Clinical significance of defective dendritic cell differentiation in cancer","volume":"6","author":"Almand","year":"2000","journal-title":"Clin Cancer Res"},{"key":"ref55","first-page":"13076","article-title":"Efficacy of DC-CIK-based immunotherapy combined with chemotherapy in the treatment of intermediate to advanced non-small cell lung cancer","volume":"13","author":"Wang","year":"2021","journal-title":"Am J Transl Res"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.3389\/fimmu.2020.01903","article-title":"The production of pro-angiogenic VEGF-A isoforms by hypoxic human NK cells is independent of their TGF-\u03b2-mediated conversion to an ILC1-like phenotype","volume":"11","author":"Hawke","year":"2020","journal-title":"Front Immunol"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ccell.2014.10.006","article-title":"Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia","volume":"26","author":"Jain","year":"2014","journal-title":"Cancer Cell"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1186\/s12943-024-02167-9","article-title":"Clinical advances and challenges in targeting FGF\/FGFR signaling in lung cancer","volume":"23","author":"Peng","year":"2024","journal-title":"Mol Cancer"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3892\/etm_00000026","article-title":"Genome-wide comparison of FGFRL1 with structurally related surface receptors","volume":"1","author":"Zhuang","year":"2010","journal-title":"Exp Ther Med"},{"key":"ref60","first-page":"21","article-title":"Phase II study of dovitinib in patients progressing on anti-vascular endothelial growth factor therapy","volume":"10","author":"Semrad","year":"2017","journal-title":"Cancer Treat Res Commun"},{"key":"ref61","first-page":"14","article-title":"HDGF enhances VEGF-dependent angiogenesis and FGF-2 is a VEGF-independent angiogenic factor in non-small cell lung cancer","volume":"44","author":"Eguchi","year":"2020","journal-title":"Oncol Rep"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/s41598-020-79907-6","article-title":"Increased VEGF-A in solid type of lung adenocarcinoma reduces the patients\u2019 survival","volume":"11","author":"Jung","year":"2021","journal-title":"Sci Rep"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"9343","DOI":"10.3390\/ijms24119343","article-title":"VE-cadherin in cancer-associated angiogenesis: a deceptive strategy of blood vessel formation","volume":"24","author":"Delgado-Bellido","year":"2023","journal-title":"Int J Mol Sci"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0167-4889(94)90016-7","article-title":"Vascular endothelial growth factor\/vascular permeability factor is detectable in the sera of tumor-bearing mice and cancer patients","volume":"1221","author":"Kondo","year":"1994","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1080\/07357900600894781","article-title":"Serum vascular endothelial growth factor (VEGF) and bcl-2 levels in advanced stage non-small cell lung cancer","volume":"24","author":"Tas","year":"2006","journal-title":"Cancer Invest"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/SMJ.0b013e318164e432","article-title":"The role of serum vascular endothelial growth factor and matrix metalloproteinase-9 in predicting response to chemotherapy in patients with advanced nonsmall cell lung cancer","volume":"101","author":"Yazar","year":"2008","journal-title":"South Med J"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1177\/172460080301800209","article-title":"Changes in circulating VEGF levels in relation to clinical response during chemotherapy for metastatic cancer","volume":"18","author":"Lissoni","year":"2003","journal-title":"Int J Biol Markers"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2147\/OTT.S124124","article-title":"Elevated serum levels of vascular endothelial growth factor predict a poor prognosis of platinum-based chemotherapy in non-small cell lung cancer","volume":"10","author":"Zang","year":"2017","journal-title":"Onco Targets Ther"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s00262-020-02539-2","article-title":"Predictive value of serum VEGF levels for elderly patients or for patients with poor performance status receiving anti-PD-1 antibody therapy for advanced non-small-cell lung cancer","volume":"69","author":"Shibaki","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"421","DOI":"10.3390\/cancers17030421","article-title":"Soluble PD-L1 and serum vascular endothelial growth factor-B may independently predict prognosis in patients with advanced non-small cell lung cancer treated with pembrolizumab","volume":"17","author":"Kokkotou","year":"2025","journal-title":"Cancers"},{"key":"ref71","first-page":"259","article-title":"Bevacizumab in the treatment of NSCLC: patient selection and perspectives","volume":"8","author":"Russo","year":"2017","journal-title":"Lung Cancer"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N Engl J Med"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/S1470-2045(17)30691-5","article-title":"Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial","volume":"18","author":"Wakelee","year":"2017","journal-title":"Lancet Oncol"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(14)60845-X","article-title":"Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial","volume":"384","author":"Garon","year":"2014","journal-title":"Lancet"},{"key":"ref75","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1124\/jpet.117.244129","article-title":"Triple angiokinase inhibitor nintedanib directly inhibits tumor cell growth and induces tumor shrinkage via blocking oncogenic receptor tyrosine kinases","volume":"364","author":"Hilberg","year":"2018","journal-title":"J Pharmacol Exp Ther"},{"key":"ref76","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S1470-2045(13)70586-2","article-title":"Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial","volume":"15","author":"Reck","year":"2014","journal-title":"Lancet Oncol"},{"key":"ref77","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.lungcan.2020.08.004","article-title":"Non-interventional LUME-BioNIS study of nintedanib plus docetaxel after chemotherapy in adenocarcinoma non-small cell lung cancer: a subgroup analysis in patients with prior immunotherapy","volume":"148","author":"Reck","year":"2020","journal-title":"Lung Cancer"},{"key":"ref78","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.cell.2018.09.035","article-title":"A paradigm shift in cancer immunotherapy: from enhancement to normalization","volume":"175","author":"Sanmamed","year":"2018","journal-title":"Cell"},{"key":"ref79","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40425-018-0316-z","article-title":"Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations","volume":"6","author":"Gong","year":"2018","journal-title":"J Immunother Cancer"},{"key":"ref80","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.molcel.2019.09.030","article-title":"Mechanisms controlling PD-L1 expression in cancer","volume":"76","author":"Cha","year":"2019","journal-title":"Mol Cell"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.ccell.2020.09.001","article-title":"The PD-1\/PD-L1-checkpoint restrains T cell immunity in tumor-draining lymph nodes","volume":"38","author":"Dammeijer","year":"2020","journal-title":"Cancer Cell"},{"key":"ref82","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.lungcan.2019.01.004","article-title":"PD-L1 protein expression in non-small-cell lung cancer and its relationship with the hypoxia-related signaling pathways: a study based on immunohistochemistry and RNA sequencing data","volume":"129","author":"Koh","year":"2019","journal-title":"Lung Cancer"},{"key":"ref83","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1002\/med.21632","article-title":"Targeting B7-1 in immunotherapy","volume":"40","author":"Chen","year":"2020","journal-title":"Med Res Rev"},{"key":"ref84","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.3390\/cancers12051089","article-title":"Scientific rationale for combined immunotherapy with PD-1\/PD-L1 antibodies and VEGF inhibitors in advanced hepatocellular carcinoma","volume":"12","author":"Kudo","year":"2020","journal-title":"Cancers"},{"key":"ref85","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N Engl J Med"},{"key":"ref86","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1200\/JCO.23.02166","volume":"42","author":"Neal","year":"2024","journal-title":"J Clin Oncol"},{"key":"ref87","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","article-title":"Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth","volume":"10","author":"Yakes","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"ref88","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/978-3-319-91442-8_13","author":"Zsch\u00e4bitz","year":"2018","journal-title":"Small molecules in oncology"},{"key":"ref89","doi-asserted-by":"crossref","first-page":"CT289","DOI":"10.1158\/1538-7445.AM2020-CT289","article-title":"Pembrolizumab plus lenvatinib vs docetaxel in patients with previously treated metastatic non-small-cell lung cancer (NSCLC) and PD after platinum doublet chemotherapy and immunotherapy: phase 3, randomized, open-label LEAP-008 trial","volume":"80","author":"Leighl","year":"2020","journal-title":"Cancer Res"},{"key":"ref90","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(24)02722-3","article-title":"Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China","volume":"405","author":"Xiong","year":"2025","journal-title":"Lancet"},{"key":"ref91","first-page":"100249","article-title":"Association between continuous decrease of plasma VEGF-A levels and the efficacy of chemotherapy in combination with anti-programmed cell death 1 antibody in non-small cell lung cancer patients","volume":"25","author":"Tozuka","year":"2020","journal-title":"Cancer Treat Res Commun"}],"container-title":["Oncology Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/cdn.techscience.cn\/files\/or\/2025\/TSP_OR-33-10\/OncolRes-33-10-66228\/OncolRes-33-66228.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T02:16:39Z","timestamp":1763345799000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.techscience.com\/or\/v33n10\/63882"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":91,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025]]},"published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.32604\/or.2025.066228","relation":{},"ISSN":["1555-3906"],"issn-type":[{"value":"1555-3906","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}